Earnings call transcript: iFabric Corp Q4 2025 sees stock surge 15.76%

iFabric reported FY2025 revenue CAD 32.9M (+20% YoY) and Q4 revenue CAD 11.0M (+5% YoY) while FY gross margin fell to 32% from 41% and adjusted EBITDA declined to CAD 1.9M (from CAD 2.7M). Management provided very strong Q1 2026 revenue guidance of CAD 25–27M (implying +127–137% YoY), prompting a 15.76% stock jump to CAD 3.82; cash rose to CAD 3.8M while inventory increased to CAD 21M. Company cites tariff impacts (seeking a ~USD 600k refund (~CAD 800k)), strategic brand transitions and ERP/investment costs as margin headwinds but expects margin recovery as tariffs ease and high-margin intimates and scrubs ramp; adj. EBITDA margin targets are ~15% in 2026 and ~20% in 2027.

Analysis

iFabric’s combination of clinically-validated textile technology and newly owned branding materially increases its ability to capture gross-margin upside versus being a pure-license OEM; that structural change is the engine investors are paying for, not one quarter’s numbers. Retail partners with national scale will act as multipliers if reorder cadence holds, but the same retail-channel concentration that accelerates growth also amplifies demand volatility and negotiating pressure on trade promotions.

The largest operational lever to monitor is working-capital conversion: a front-loaded inventory position funded with credit lines and FX-driven cash-management decisions creates a narrow window where execution and sell-through must match expectations or margin dilution and covenant pressure materialize. Binary catalysts (regulatory labeling for the antimicrobial claim and an administratively-timed tariff refund) will create lumpy P&L/operating-cash inflection points — each can re-rate the equity quickly, but both are binary and timing is uncertain.

Market reaction has priced a story of rapid margin normalization; the contrarian risk is that premium ASPs and hospital/B2B adoption prove slower than retail rollouts and that some replenishment is promotional-led rather than sticky. The optimal way to capture upside is through asymmetric, event-aware structures that limit downside to the next retail cadence while leaving room for multiplex expansion if institutional adoption and regulatory wins arrive as hoped.

Key Decisions for Investors

• Long IFA.TO (tactical core): Accumulate on pullbacks of ~5-12% from current levels, position size 1-2% of NAV. Hold 9–18 months to capture margin recovery and retail rollouts; trim into any >60% rally. Risk management: hard stop at 25% loss from entry given working-capital and execution risk (target ~3:1 reward:risk if catalysts land).
• Options event play (regulated upside, capped cost): Buy a 9–12 month IFA.TO call-debit spread (near-the-money long call / higher strike short) sized for 0.5–1% NAV to play regulatory/tariff catalysts. Rationale: limited premium outlay, leveraged upside if EPA claim or outsized reorder waves occur, capped downside to premium paid.
• Hedge/insurance alternative: Buy a 9–12 month out-of-the-money put (protect 50–60% of the position) for investors holding stock facing inventory/sell-through risk. This converts a directional bet into a defined-loss, catalyst-driven trade — sensible if position is >2% NAV.
• Relative-value guard: Avoid pairing IFA.TO with exposure to commodity, low-differentiation apparel suppliers; instead, neutralize retail exposure by underweighting non-differentiated private-label apparel suppliers and favoring retailers with stable gross-margins and scale (use this tactically while IFA proves sell-through).